BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 35996877)

  • 21. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
    Freise KJ; Shebley M; Salem AH
    J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
    Bhatnagar S; Mukherjee D; Salem AH; Miles D; Menon RM; Gibbs JP
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):465-474. PubMed ID: 33398386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice.
    Le Louedec F; Puisset F; Chatelut E; Tod M
    Clin Pharmacokinet; 2023 Jan; 62(1):55-66. PubMed ID: 36631685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.
    Wang X; Chen F; Guo N; Gu Z; Lin H; Xiang X; Shi Y; Han B
    Cancer Chemother Pharmacol; 2023 Oct; 92(4):253-270. PubMed ID: 37466731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
    Rowland Yeo K; Gil Bergland E; Chen Y
    Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38686708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
    Mukherjee D; Brackman DJ; Suleiman AA; Zha J; Menon RM; Salem AH
    J Clin Pharmacol; 2023 Jan; 63(1):119-125. PubMed ID: 35996877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
    Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
    Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
    Waldron M; Winter A; Hill BT
    Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.